Douglas Jermasek's Insider Trades & SAST Disclosures
Douglas Jermasek's most recent trade in Unicycive Therapeutics Inc was a trade of 81,750 Stock Options done . Disclosure was reported to the exchange on Aug. 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Douglas Jermasek.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 81,750 | 2,055,000 | - | - | Stock Options | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 463,250 | 1,973,250 | - | - | Stock Options | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 1,355,000 | 1,510,000 | - | - | Stock Options | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 115,275 | 115,275 | - | - | Warrant (right to buy) | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 104,612 | 175,012 | - | - | Common Stock | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 79,252 | 79,252 | - | - | Warrant (right to buy | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 72,047 | 72,047 | - | - | Warrant (right to buy) | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2023 | 50 | 0 | - | - | Series A-1 Convertible Preferred Stock | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 50 | 50 | - | - | Series A Convertible Preferred Stock | |
| Unicycive Therapeutics Inc | Douglas Jermasek | EVP of Corporate Strategy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2022 | 55,000 | 155,000 | - | - | Stock Options |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges